innerbuddies gut microbiome testing

Gut Microbiome and Coronary Artery Disease Risk: Latest Research Insights

For years, coronary artery disease (CAD) research has focused on cholesterol, blood pressure, smoking, and diabetes—but the gut microbiome has emerged as another key “upstream” factor that may shape an individual’s cardiovascular risk. The trillions of microbes in your intestines help process dietary fibers, produce bioactive metabolites, and regulate immune signaling, all of which can influence how your body responds to vascular inflammation—the process closely tied to plaque development.

Recent studies show that not all gut microbes affect the heart in the same way. Some microbial communities appear more strongly associated with protective cardiovascular profiles, partly through producing beneficial compounds such as short-chain fatty acids (SCFAs) that can support gut barrier integrity and help dampen systemic inflammation. Others may contribute to harmful pathways, including altered bile acid metabolism and immune activation, and in certain cases increased production of metabolites linked to atherosclerosis risk.

What’s driving current interest is how the gut microbiome may connect diet, inflammation, and plaque biology. Microbial metabolites such as trimethylamine (TMA) derivatives and lipopolysaccharide (LPS)-related signaling are being investigated for their roles in endothelial dysfunction and pro-inflammatory immune responses. As evidence grows, this research is moving beyond “association” toward potential applications—risk stratification, improved biomarkers, and personalized nutrition strategies designed to promote beneficial bacteria and reduce harmful metabolic outputs.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Coronary artery disease risk context

Emerging research links the gut microbiome to coronary artery disease (CAD) risk by shaping inflammation, lipid metabolism, and vascular function. Microbes convert dietary nutrients such as choline and phosphatidylcholine (found in eggs) and L-carnitine (abundant in red meat) into trimethylamine (TMA), which the liver oxidizes to trimethylamine N-oxide (TMAO). Higher TMAO levels have been associated with increased CAD risk and may promote platelet reactivity, altered cholesterol handling, and inflammation. In contrast, short-chain fatty acids (SCFAs) like butyrate—produced when fiber is fermented—support gut barrier integrity, modulate immune responses, and favor metabolic profiles that protect against atherosclerosis. The balance of these microbial metabolites, rather than any single organism, appears to drive CAD risk.

Clinically, microbiome patterns offer potential early biomarkers for CAD risk and may guide personalized prevention. Diet and interventions that boost cardioprotective SCFA production or reduce TMA/TMAO signaling are among the strategies being explored, alongside more precise microbiome-targeted therapies. Although causality and population differences require further study, the microbiome lens complements traditional risk factors like LDL cholesterol, blood pressure, and diabetes by revealing upstream biological signals contributing to endothelial dysfunction and plaque progression.

Health tools such as InnerBuddies aim to illuminate CAD risk by profiling gut microbiome activity and metabolite output, providing actionable context for clinicians and patients. By identifying whether a person’s microbiome leans toward TMAO-producing pathways or SCFA-driven protection, care plans can be tailored—emphasizing fermentable fiber intake and other lifestyle changes to shift the metabolic balance toward lower vascular inflammation and healthier endothelial function, potentially before symptoms like chest pain, shortness of breath, or leg swelling appear.

  • TMA/TMAO pathway links gut microbial metabolism of choline, phosphatidylcholine (eggs) and L-carnitine (red meat) to higher CAD risk via platelet hyperreactivity, altered cholesterol handling, and inflammatory signaling.
  • Elevated risk taxa associated with TMA/TMAO production include Eggerthella lenta; Escherichia coli/Shigella; Enterococcus; Streptococcus; Bacteroides (TMA-producing groups); Alistipes; and the Ruminococcus gnavus group.
  • Beneficial SCFA-producing taxa such as Faecalibacterium prausnitzii; Roseburia spp.; Eubacterium rectale; Coprococcus spp.; Anaerostipes spp.; Butyrivibrio spp.; Bifidobacterium longum; and Akkermansia muciniphila support gut barrier integrity and anti-inflammatory responses.
  • Butyrate and other SCFAs strengthen gut barrier, modulate immunity, and improve lipid/glucose metabolism, contributing to lower systemic inflammation and potentially slower atherosclerosis progression.
  • Dysbiosis can increase gut permeability and endotoxemia (LPS), triggering vascular immune activation and endothelial dysfunction, an early step in CAD.
  • The overall microbiome metabolite pattern—rather than any single microbe—predicts risk, balancing proinflammatory/TMAO-like signals with protective SCFA-driven pathways.
  • Microbiome testing can reveal TMAO-producing potential and SCFA-producing capacity, informing personalized prevention strategies (e.g., dietary shifts toward fermentable fiber).
  • Dietary guidance from this perspective emphasizes fermentable fiber to boost SCFAs and cautions against high intake of choline/phosphatidylcholine and L-carnitine–rich foods (eggs, red meat) to modulate TMAO production.
  • Clinically, microbiome-derived signatures may serve as early biomarkers and help tailor prevention before CAD symptoms such as chest pain or reduced exercise tolerance emerge.
Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cardiovascular risk-related topics

Research increasingly links the gut microbiome to coronary artery disease (CAD) risk by showing that the intestinal ecosystem can influence inflammation, lipid metabolism, and vascular function—processes that drive atherosclerotic plaque development. Certain bacterial communities are associated with a higher inflammatory tone, altered bile acid profiles, and changes in how the body handles dietary fats and sugars. Over time, these microbiome-driven shifts can contribute to endothelial dysfunction (the earliest step in atherosclerosis), promote immune activation in vessel walls, and accelerate plaque formation and progression.

A growing body of evidence highlights both “harmful” and “beneficial” microbial pathways. For example, microbial conversion of dietary nutrients can produce metabolites implicated in cardiovascular risk. Trimethylamine (TMA), derived from compounds in foods such as choline, phosphatidylcholine (e.g., eggs), and L-carnitine (e.g., red meat), is converted by the liver to trimethylamine N-oxide (TMAO), which has been associated with higher CAD risk and may promote platelet hyperreactivity, cholesterol handling changes, and inflammation. Other microbial metabolites—including short-chain fatty acids (SCFAs) like butyrate—are generally considered protective due to their roles in strengthening gut barrier integrity, modulating immune responses, and influencing lipid and glucose metabolism. The balance of these microbial metabolites, rather than any single organism, appears to be central.

Clinically, this line of research is shaping future prevention and personalization strategies. Potential applications include using microbiome and metabolite patterns as early biomarkers for CAD risk, improving dietary recommendations to encourage cardioprotective microbial functions (for instance, fiber-rich dietary patterns that increase SCFAs), and targeting harmful pathways (such as modulating TMA/TMAO production via diet or, in some approaches, therapeutics). While the field is still evolving—with ongoing studies needed to clarify causality, population differences, and reproducibility—the overall direction is clear: gut microbiome composition and microbial metabolite output may offer a complementary, mechanistic lens on CAD risk beyond traditional factors.

  • Chest pain or pressure (angina), especially with exertion or stress
  • Shortness of breath during physical activity
  • Reduced exercise tolerance and easy fatigue
  • Palpitations or an irregular heartbeat feeling
  • Swelling in the legs/ankles (fluid retention, sometimes linked to heart strain)
  • Numbness, pain, or discomfort in the arms, back, neck, or jaw (referred discomfort)
  • Dizziness or lightheadedness
Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Coronary artery disease risk context

This information is most relevant for people at elevated risk for coronary artery disease (CAD) or who are in the early stages of cardiovascular disease prevention—especially those who want to understand how diet and gut health may influence inflammation, cholesterol handling, and blood-vessel function. It can also be useful for individuals with strong traditional risk factors (e.g., metabolic syndrome, diabetes, high LDL/low HDL patterns, smoking history, or family history), where an added “gut microbiome and metabolite” lens may help explain why risk remains even when lifestyle changes are underway. People interested in personalized prevention and early risk biomarkers may find the TMA/TMAO and short-chain fatty acid (SCFA) pathways particularly relevant.

It may also be relevant for adults experiencing symptoms consistent with possible CAD—such as chest pressure or pain (often with exertion or stress), shortness of breath with activity, reduced exercise tolerance, or palpitations. While these symptoms require prompt medical evaluation to rule out urgent cardiac causes, microbiome-linked mechanisms (heightened inflammatory tone, altered bile acid profiles, and endothelial dysfunction) provide a plausible pathway connecting gut-derived metabolites to vascular inflammation and atherosclerotic progression. This is especially pertinent for those whose lifestyle includes frequent red meat/egg-heavy patterns (higher choline/carnitine substrates for TMA production) and low fiber intake (less support for SCFA-generating bacteria).

Additionally, this content is relevant for people who are actively managing cardiometabolic conditions or considering dietary changes aimed at cardiovascular risk reduction—such as adopting a fiber-rich eating pattern (to support butyrate and other SCFAs) or reducing dietary inputs associated with higher TMA/TMAO formation. It can guide discussions with clinicians or dietitians about how gut-ecosystem outputs might complement standard care, not replace it—particularly when symptoms overlap with cardiovascular strain like leg/ankle swelling or fatigue. Overall, it’s a good fit for anyone seeking a mechanistic, gut-focused approach to prevention, risk monitoring, and nutrition strategies aligned with cardiovascular outcomes.

Coronary artery disease (CAD) is one of the most common cardiovascular conditions worldwide and is a major contributor to heart-related death and disability. In global terms, estimates suggest that roughly 110–130 million people are living with CAD, and its prevalence rises steeply with age; in many countries, it affects about 1–2% of adults overall, with substantially higher rates in older age groups (often exceeding 10% in those aged 70+). Because the gut microbiome is increasingly linked to CAD through inflammation, lipid metabolism, and vascular function, researchers are also investigating whether microbiome-driven risk pathways may be present alongside (and potentially earlier than) traditional risk factors such as high LDL-C, diabetes, and hypertension.

When CAD becomes symptomatic, the clinical picture often includes classic features like exertional chest pressure/pain (angina), reduced exercise tolerance, shortness of breath with activity, and referred discomfort to the arms, back, neck, or jaw. These symptoms are commonly reported during periods of insufficient blood flow to the heart muscle; however, not everyone with CAD has obvious symptoms—some have “silent” disease—so population prevalence based purely on symptom reports can undercount true disease burden. Still, among people with known cardiovascular risk factors (e.g., smoking, diabetes, dyslipidemia), symptom prevalence can be high, and CAD-related presentations account for a large share of emergency and outpatient cardiovascular visits in many health systems.

From a microbiome-research standpoint, it’s important to distinguish “prevalence of CAD” from “prevalence of gut microbiome patterns associated with higher CAD risk.” There is no single agreed percentage for having a “CAD-high-risk microbiome,” because patterns vary by diet, geography, medications (notably antibiotics and proton pump inhibitors), and measurement methods (16S vs. metagenomics and metabolite profiling). Nonetheless, studies show that gut microbial communities associated with higher TMA/TMAO signaling (driven by microbial conversion of choline, phosphatidylcholine, and L-carnitine) and lower production of protective short-chain fatty acids (SCFAs like butyrate) are relatively common in populations consuming lower fiber diets and higher intakes of red meat or egg-derived phosphatidylcholine—nutritional patterns that often correlate with higher rates of CAD and related cardiometabolic disorders.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Coronary Artery Disease Risk: What the Latest Research Shows

Coronary artery disease (CAD) risk is increasingly connected to the gut microbiome through its ability to shape inflammation, lipid metabolism, and vascular function. The intestinal ecosystem can influence immune signaling and the production of microbial metabolites that affect endothelial health—the earliest step in atherosclerosis. Over time, microbiome-driven changes in gut barrier integrity and inflammatory tone may contribute to vessel wall immune activation, promoting plaque formation and progression. This offers a mechanistic “extra layer” on top of classic CAD risk factors such as cholesterol, blood pressure, and diabetes.

One key pathway involves microbial conversion of dietary nutrients into metabolites linked with cardiovascular risk. Trimethylamine (TMA), produced from choline, phosphatidylcholine (found in eggs), and L-carnitine (abundant in red meat), is converted in the liver to trimethylamine N-oxide (TMAO). Higher TMAO levels have been associated with increased CAD risk and may promote platelet hyperreactivity, altered cholesterol handling, and heightened inflammation—biologic processes that align with symptoms like chest pressure (angina), reduced exercise tolerance, and shortness of breath during activity. The overall pattern of microbial metabolic output, rather than a single organism, appears to be central.

Conversely, other gut-derived metabolites—especially short-chain fatty acids (SCFAs) such as butyrate—are generally viewed as cardioprotective. SCFAs support gut barrier strength, help modulate immune responses, and influence glucose and lipid regulation, which can reduce systemic inflammatory signals that worsen vascular function. Diets that increase fermentable fiber tend to favor SCFA-producing pathways, potentially steering the gut ecosystem toward a more protective metabolic profile. As research advances, microbiome and metabolite signatures may become early biomarkers and guide personalized prevention strategies aimed at lowering CAD risk before symptoms such as chest pain, palpitations, dizziness, or leg swelling emerge.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Coronary artery disease risk context

  • Microbial metabolites that drive atherogenesis (e.g., TMA → TMAO) from choline/phosphatidylcholine/L-carnitine can promote vascular inflammation, alter cholesterol handling, and increase platelet hyperreactivity—processes tied to CAD symptoms like exertional chest pressure and reduced exercise tolerance.
  • Endothelial dysfunction via inflammatory signaling: gut dysbiosis and metabolite patterns can increase circulating pro-inflammatory mediators that impair endothelial nitric oxide balance and weaken vascular function, accelerating early atherosclerotic changes.
  • Reduced gut barrier integrity and endotoxemia: loss of tight-junction strength can permit microbial components (e.g., LPS) to enter circulation, amplifying systemic immune activation that contributes to plaque formation and progression.
  • Immune pathway shaping (innate and adaptive): microbiome-driven changes in immune tone (regulatory T cells, Th17 balance, cytokine profiles) can increase vascular immune cell recruitment and sustain plaque-active inflammation.
  • SCFA-mediated protection from fermentable fiber: beneficial fermentation (e.g., butyrate and other SCFAs) supports gut barrier function, modulates inflammation, and improves metabolic regulation of glucose and lipids that lower CAD risk.
  • Metabolic reprogramming affecting lipid metabolism and reverse cholesterol transport: microbiome-derived signals can influence bile acid transformation and host lipid pathways, altering cholesterol availability and potentially affecting atherosclerosis trajectory.

Coronary artery disease risk is increasingly tied to the gut microbiome because intestinal microbes shape inflammation, lipid handling, and vascular function through the metabolites they produce. Certain nutrient inputs—especially choline, phosphatidylcholine (common in eggs), and L-carnitine (abundant in red meat)—can be converted by gut microbes into trimethylamine (TMA). The liver then transforms TMA into trimethylamine N-oxide (TMAO), which has been associated with higher CAD risk. TMAO is thought to contribute to atherosclerosis by promoting platelet hyperreactivity, altering cholesterol-related processes, and amplifying inflammatory signaling—mechanisms that can manifest clinically as exertional chest pressure, reduced exercise tolerance, and shortness of breath.

Gut dysbiosis can also undermine endothelial health by increasing systemic inflammatory tone. When the microbial ecosystem shifts, pro-inflammatory mediators may rise and disrupt the normal balance of nitric oxide in the endothelium, weakening vessel relaxation and accelerating early atherosclerotic change. In parallel, reduced gut barrier integrity can allow microbial products such as LPS to cross into circulation (endotoxemia), triggering innate and adaptive immune activation. This creates a loop of vascular immune recruitment and sustained plaque-active inflammation, driven by microbiome-influenced immune pathways that alter regulatory T cell activity and Th17/cytokine profiles.

Not all microbial metabolites increase risk—some appear protective, especially those generated through fermenting fiber. Beneficial fermentation can increase short-chain fatty acids (SCFAs) like butyrate, which support tight-junction strength and improve gut barrier integrity. SCFAs also modulate immune responses and influence metabolic regulation of glucose and lipids, lowering systemic inflammatory signals that worsen vascular function. Additionally, microbiome-driven metabolic reprogramming can alter bile acid transformations and host lipid pathways, potentially shifting cholesterol availability and reverse cholesterol transport in ways that reduce atherosclerosis progression. Together, these mechanisms highlight how the overall microbiome metabolite “pattern” can act as an extra layer on top of classic CAD risk factors.

Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In coronary artery disease risk, gut microbiome–linked patterns often center on metabolite output that promotes vascular inflammation and prothrombotic behavior. Diet-derived nutrients such as choline, phosphatidylcholine (notably from eggs), and L-carnitine (abundant in red meat) can be metabolized by intestinal microbes into trimethylamine (TMA), which the liver converts into trimethylamine N-oxide (TMAO). Higher TMAO-associated metabolic profiles have been linked with increased CAD risk through pathways that may include platelet hyperreactivity, altered cholesterol handling, and amplification of inflammatory signaling—processes that align with symptoms like exertional chest pressure and reduced exercise tolerance.

Alongside TMAO-related signals, many CAD-associated microbiome patterns reflect a shift toward greater inflammatory tone and weaker gut barrier function. Gut dysbiosis can change immune signaling by increasing permeability, allowing microbial products such as lipopolysaccharide (LPS) to enter circulation and trigger innate and adaptive immune activation. This can contribute to endothelial dysfunction by disturbing nitric-oxide balance and promoting vascular immune recruitment, creating a feedback loop that sustains plaque-active inflammation and accelerates early atherosclerotic change over time.

In contrast, more protective microbiome patterns are frequently characterized by a greater capacity to ferment dietary fibers into beneficial short-chain fatty acids (SCFAs) such as butyrate. These metabolite profiles are associated with stronger gut tight junctions, improved barrier integrity, and immune modulation that can lower systemic inflammatory signals that otherwise worsen vascular function. They may also support healthier bile acid transformations and metabolic regulation of glucose and lipids, shifting the overall host metabolic environment away from atherosclerosis progression—suggesting that the balance of microbial metabolite patterns, rather than a single organism, is a key driver of CAD risk.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Anaerostipes spp.
  • Bifidobacterium longum
  • Akkermansia muciniphila
  • Butyrivibrio spp.
  • Coprococcus spp.


Elevated / overrepresented taxa

  • Ruminococcus gnavus group
  • Enterococcus spp.
  • Streptococcus spp.
  • Eggerthella lenta
  • Alistipes spp.
  • Escherichia coli/Shigella spp.
  • Proteobacteria (Enterobacteriaceae family)
  • Bacteroides (TMA-producing bile-tolerant groups)


Functional pathways involved

  • Choline/phosphatidylcholine–to–TMA–to–TMAO metabolic pathway (microbial TMA production and hepatic TMAO generation)
  • L-carnitine–to–TMA microbial conversion pathway (red-meat associated precursor utilization)
  • Pro-inflammatory endotoxin (LPS) translocation and innate immune activation pathway via increased gut permeability (TLR4/NF-κB signaling)
  • SCFA (butyrate) biosynthesis and epithelial barrier support pathway (tight junction maintenance, anti-inflammatory signaling)
  • Bile acid transformation by gut microbes (bile acid deconjugation/secondary bile acid signaling affecting FXR/TGR5 and lipid/glucose regulation)
  • Platelet hyperreactivity and thrombosis-linked signaling pathway modulated by TMAO (e.g., platelet activation/foam cell–related vascular effects)
  • Gut-derived inflammatory metabolite signaling affecting endothelial dysfunction (nitric-oxide balance and immune cell recruitment pathways)
  • Proteobacteria-associated dysbiosis pathway (enteric pathogen–like expansion contributing to inflammatory tone and reduced colonization resistance)


Diversity note

In coronary artery disease (CAD) risk contexts, researchers often observe gut microbiome changes that reflect a shift away from a highly diverse, stable community toward a more dysbiotic pattern. This can mean reduced richness/evenness and a lower abundance of microbes associated with beneficial metabolite production, alongside enrichment of taxa linked with pro-inflammatory signaling. Functionally, the community tends to favor metabolic outputs that can worsen vascular inflammation, which aligns with CAD biology where endothelial dysfunction and immune activation help drive plaque formation.

A common theme is that less diverse or dysbiotic microbiomes are associated with impaired gut barrier integrity and altered immune signaling. When barrier function weakens, microbial products can more readily influence systemic inflammation, potentially amplifying endothelial dysfunction and creating a feedback loop that sustains atherosclerotic activity. At the same time, the balance of microbial metabolism may shift toward metabolites associated with higher cardiovascular risk, such as TMA-derived pathways that ultimately increase TMAO levels.

In contrast, CAD-risk–protective microbiome profiles are more often linked with preserved diversity and stronger “ecological function,” particularly the capacity to ferment dietary fibers into short-chain fatty acids (SCFAs) like butyrate. These metabolites tend to support tight junctions, modulate immune responses, and help normalize aspects of lipid and glucose handling, which can reduce systemic inflammatory tone that otherwise promotes vascular injury. Overall, it’s the combination of diversity changes and metabolite-producing capacity—rather than a single organism—that typically characterizes microbiome patterns seen in CAD risk.


Get Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic gut-microbiome solutions often fail in coronary artery disease (CAD) risk because the drivers are not simply “more probiotics” or “more fiber” in isolation. CAD-linked microbiome effects are frequently mediated by specific microbial metabolic outputs—especially nutrient-to-metabolite pathways like choline, phosphatidylcholine (eggs), and L-carnitine (red meat) converting to TMA and then TMAO in the liver. Without addressing the individual pattern of gut metabolite production and how an individual’s diet and bile acid milieu feed those pathways, a generic approach may miss the central mechanism that promotes platelet hyperreactivity, cholesterol handling changes, and vascular inflammation.

    They also tend to overlook that CAD risk involves an ongoing interaction between gut barrier integrity, immune signaling, and vascular endothelial function. Many people show different degrees of dysbiosis, permeability, and inflammatory set-point; generic products can improve “overall digestion” or stool consistency while leaving the key upstream issues—tight-junction support, endotoxin (e.g., LPS) translocation risk, and downstream endothelial nitric-oxide balance—largely unchanged. In other words, symptom-agnostic supplementation may not reliably reduce the inflammatory feedback loop that sustains plaque-active immune recruitment.

    Finally, gut ecology is highly personalized, so a one-size-fits-all intervention can inadvertently shift the microbiome in the wrong direction. For example, some generic plans emphasize broad supplementation without calibrating fermentable substrate intake or without considering how existing bile acid transformations, medication use (e.g., antibiotics, PPIs, statins), and baseline dietary patterns shape SCFA production. Since protective signals like butyrate-linked barrier and immune modulation depend on a supportive ecosystem, the same “generic” regimen can produce negligible benefits—or variable results—across individuals, limiting its effectiveness for CAD risk reduction.

  • Common mistakes

    • Focusing on generic “probiotics” without targeting the CAD-relevant metabolite pathway (e.g., choline/phosphatidylcholine/L-carnitine → TMA → TMAO), leaving platelet hyperreactivity and inflammatory signaling largely unaddressed
    • Using “more fiber” as a one-size-fits-all lever without ensuring fermentable fiber is actually converted into protective SCFAs (e.g., butyrate) and without accounting for baseline microbiome function
    • Ignoring gut barrier and endotoxin translocation risk (e.g., LPS crossing into circulation), so interventions may improve stool quality while not reducing systemic immune activation and endothelial dysfunction
    • Overlooking diet-to-microbe specificity—failing to calibrate red meat and egg/choline intake (and other TMAO substrates) to the person’s microbial capacity to produce TMA
    • Not considering bile acid context and host factors that shape microbial metabolism (e.g., bile acid transformations that influence inflammatory tone and cholesterol handling)
    • Failing to account for medication effects and disrupted ecology (common in CAD), such as antibiotics, PPIs, and statins that can shift microbial composition and metabolite outputs
    • Assuming uniform response across individuals instead of personalizing based on baseline dysbiosis, permeability/inflammation set-point, and existing SCFA/TMAO-related metabolic patterns
    • Treating symptoms (bloating, irregularity) or general digestion improvements as proxies for CAD risk reduction, rather than measuring whether downstream vascular/immune pathways are being modulated

What to do

  • General support strategies

    Coronary artery disease (CAD) risk is increasingly understood through the gut microbiome’s effects on inflammation, lipid handling, and vascular function. A key support strategy is to encourage a gut ecosystem that produces a more cardioprotective metabolic output—favoring pathways that strengthen the intestinal barrier and keep immune activation in check. When gut permeability increases and inflammatory signaling rises, it can amplify early endothelial dysfunction, helping create a fertile environment for atherosclerosis to progress. Supporting gut barrier integrity and reducing chronic low-grade inflammation can therefore act as an “extra layer” of prevention alongside classic risk factors like cholesterol management, blood pressure control, and diabetes care.

    Diet is central to shaping these microbial metabolites. Diets higher in fermentable fiber (from vegetables, legumes, whole grains, nuts, and seeds) tend to promote production of short-chain fatty acids (SCFAs) such as butyrate, which are generally associated with improved gut barrier strength, better immune regulation, and more favorable glucose and lipid metabolism. At the same time, limiting dietary patterns that increase substrates for pro-atherogenic metabolites—particularly those that supply high amounts of choline and L-carnitine from sources like eggs and red meat—may help reduce the microbial-to-hepatic pathway that leads to trimethylamine (TMA) and its metabolite TMAO. While the evidence continues to evolve and responses vary by individual microbiome composition, aligning intake toward fiber-rich, minimally processed foods is a practical way to shift the balance toward protective metabolites.

    Because the microbiome responds to long-term patterns, consistency matters, and additional lifestyle factors can support the overall gut–heart axis. Regular physical activity, adequate sleep, stress reduction, and avoiding unnecessary antibiotic exposure may help maintain a stable and diverse microbial community. Over time, these combined approaches may support vascular health by lowering systemic inflammatory tone, improving metabolic signaling, and promoting healthier endothelial function—potentially helping reduce the likelihood of symptoms such as chest pressure, shortness of breath with exertion, or reduced exercise tolerance that can accompany evolving CAD.

  • Lifestyle recommendations

    • Increase dietary fiber from fruits, vegetables, legumes, and whole grains to promote beneficial SCFA-producing gut microbes and reduce inflammatory tone.
    • Reduce intake of red meat and high–choline/phosphatidylcholine-heavy foods (e.g., processed meats); choose leaner protein sources (e.g., fish, poultry, plant-based options) to lower TMA/TMAO production.
    • Limit processed foods and saturated/trans fats; follow a heart-healthy dietary pattern (e.g., Mediterranean-style) to support vascular and inflammatory health.
    • Prioritize regular exercise (as tolerated) and maintain a healthy weight, which supports metabolic health and may improve gut barrier function and immune signaling.
    • Avoid smoking and keep alcohol intake modest, since both can worsen gut permeability/inflammation and thereby increase CAD risk.

  • Nutrition recommendations

    • Increase fermentable fiber intake (e.g., beans/lentils, oats, barley, chia/flax, vegetables, berries) to boost short-chain fatty acids (SCFAs) like butyrate that support gut barrier integrity and lower systemic inflammation.
    • Reduce dietary sources that can increase TMA/TMAO risk—especially high choline/phosphatidylcholine and L-carnitine–rich foods in excess (e.g., frequent red meat and processed meats; limit egg yolks if your intake is high), while prioritizing plant-forward proteins.
    • Favor cardioprotective protein choices (fish; plant proteins such as legumes, tofu/tempeh) over frequent red/processed meat to shift gut microbial metabolism away from TMAO-promoting pathways.
    • Adopt a Mediterranean-style eating pattern (extra-virgin olive oil, nuts, legumes, whole grains, vegetables, fruits) to improve lipid handling and support a more favorable gut-metabolite profile linked to cardiovascular health.
    • Include omega-3–rich foods (fatty fish like salmon/sardines 1–2x/week, or discuss supplementation if needed) to support vascular function and help counter inflammatory signaling that contributes to atherosclerosis.
    • Limit ultra-processed foods and excess added sugars, which can worsen gut barrier function and promote inflammatory immune tone—factors associated with plaque progression.

  • Supplement considerations

    For coronary artery disease (CAD) risk reduction, gut-microbiome–targeted supplements are best thought of as ways to shift microbial metabolism toward a more cardioprotective signaling environment. A central concern in this space is the trimethylamine (TMA)–to–trimethylamine N-oxide (TMAO) pathway, where gut microbes convert choline-, phosphatidylcholine (notably from eggs), and L-carnitine (abundant in red meat) into TMA, which the liver then oxidizes to TMAO. Because higher TMAO levels have been associated with increased CAD risk, supplements that reduce TMAO-driving microbial activity (or otherwise dampen inflammatory signaling downstream of microbial metabolites) are often the focus, though effects can be individualized and depend on diet, baseline microbiome composition, and gut transit time.

    On the flip side, many supplement strategies aim to increase short-chain fatty acid (SCFA) production—especially butyrate—since SCFAs support intestinal barrier integrity and help regulate immune tone. This can translate into less systemic inflammation and improved endothelial function, which are early elements of atherosclerosis. In practice, that usually means supplementing fermentable fibers or prebiotic compounds (rather than relying solely on probiotics), because these “feed” beneficial, SCFA-producing microbes. Some individuals may also benefit from carefully selected probiotic strains when paired with a fiber-forward dietary pattern, but the strongest and most consistent lever tends to be substrate availability for SCFA formation.

    Because microbiome effects are metabolite-specific, risk modifiers like bile-acid signaling, inflammation, and platelet activity should be considered when choosing supplements. Look for products with evidence for gut barrier support, SCFA enhancement, and anti-inflammatory modulation, and be mindful that response varies—particularly in people taking standard CAD therapies (e.g., statins, antiplatelet drugs) or those with diabetes, chronic kidney disease, or gut disorders. Trialing interventions with clinician guidance, tracking relevant biomarkers when available (such as inflammatory markers or metabolite-related tests), and emphasizing dietary foundations (fiber quality, whole-food patterns) typically yields the most meaningful changes in CAD-related gut–vascular signaling.

  • Retesting / monitoring note

    For coronary artery disease (CAD) risk, gut microbiome–focused retesting is most informative when it’s used to track *changes in microbial function and metabolite output*, not just organism counts. If you’re starting from a baseline gut microbiome/metabolomics evaluation (often including markers related to TMAO and short-chain fatty acids like butyrate), a sensible retest window is typically around 8–12 weeks after meaningful diet or lifestyle adjustments. This timeframe allows the gut ecosystem to adapt and for downstream metabolites—linked to endothelial inflammation, lipid handling, and vascular immune activation—to shift in a measurable way.

    Retesting is most useful after interventions that directly influence the pathways thought to drive CAD risk. For example, changes such as increasing fermentable fiber (to support SCFA-producing communities), reducing or modulating high–TMA/TMAO precursor intake (e.g., frequent red meat and other dietary sources rich in choline/L-carnitine), and improving overall cardiometabolic targets may be followed by retesting to see whether metabolite patterns move in a cardioprotective direction. If an initial result suggested higher risk signaling (for instance, elevated TMAO or a reduced SCFA profile), clinicians and dietitians often retest to confirm whether the intervention produced a sustained metabolic shift rather than a short-term fluctuation.

    Finally, retesting should be interpreted in context of classic CAD risk factors and standard clinical biomarkers. Gut-derived signals are an “extra layer” that may help refine prevention, but they shouldn’t replace monitoring of cholesterol, blood pressure, glucose/diabetes status, and symptoms such as chest pressure, shortness of breath, or reduced exercise tolerance. In practice, many programs reassess microbiome/metabolite signatures periodically (often every 6–12 months once stable) if the goal is personalized optimization—especially when diet adherence is variable, symptoms evolve, medications change, or there’s concern that inflammation-related pathways may be progressing.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters in coronary artery disease (CAD) risk because it can reveal how your intestinal ecosystem is metabolizing diet into molecules that influence inflammation, lipid handling, and vascular function—processes that contribute to atherosclerosis. Instead of focusing only on traditional risk factors like cholesterol, blood pressure, and diabetes, microbiome testing offers an “upstream” view of the biological signals that may accelerate or dampen early vessel wall changes. By identifying patterns in microbial metabolic potential, it can help explain why two people with similar standard risk profiles may experience different degrees of immune activation and plaque progression.

    A key example is the gut-driven production of trimethylamine (TMA) and its liver-converted product, trimethylamine N-oxide (TMAO), which has been associated with higher CAD risk. Testing can provide insight into whether your microbiome is primed to generate TMAO-promoting metabolic outputs—information that may relate to downstream effects such as platelet hyperreactivity, altered cholesterol transport, and heightened inflammatory tone. This is clinically relevant because those same mechanisms are closely tied to symptoms like chest pressure (angina) and reduced exercise tolerance.

    At the same time, microbiome testing can also highlight whether your gut environment supports the formation of cardioprotective metabolites such as short-chain fatty acids (SCFAs) like butyrate. SCFAs are generally linked with stronger gut barrier integrity and more balanced immune signaling, which may reduce systemic inflammation that worsens endothelial function. Knowing your microbiome-driven metabolite profile can therefore help personalize prevention strategies—such as diet adjustments toward fermentable fiber—to shift the metabolic balance toward a more protective cardiovascular risk trajectory, potentially before symptoms emerge.

  • How InnerBuddies helps

    InnerBuddies can help illuminate coronary artery disease (CAD) risk by looking at the gut microbiome signals that sit “upstream” of classic risk factors like LDL cholesterol, blood pressure, and glycemic status. Because the intestinal ecosystem influences inflammation, lipid handling, and endothelial function, your results can provide context for how your gut environment may be shaping the biological conditions that contribute to early atherosclerosis. Instead of only tracking downstream outcomes, InnerBuddies helps you understand which microbial patterns and metabolic tendencies may be promoting or restraining vessel-wall immune activation over time.

    A major cardiovascular pathway linked to gut microbes involves trimethylamine (TMA) production from diet-derived nutrients such as choline (e.g., eggs) and L-carnitine (e.g., red meat), followed by conversion in the liver to trimethylamine N-oxide (TMAO). InnerBuddies’ insights can help characterize whether your microbiome is more likely to drive TMA/TMAO-associated metabolic profiles, which have been associated with processes like platelet hyperreactivity, altered cholesterol transport, and higher inflammatory tone. These mechanisms align with the kinds of symptoms people may notice as CAD progresses, such as chest pressure (angina) or reduced exercise tolerance.

    InnerBuddies can also support a more protective perspective by highlighting whether your gut ecosystem favors metabolites generally considered cardioprotective—particularly short-chain fatty acids (SCFAs) like butyrate. SCFAs are associated with stronger gut barrier integrity and more balanced immune signaling, which can reduce systemic inflammatory effects that harm vascular function. Armed with this metabolic and microbial context, you and your clinician can better tailor prevention strategies (for example, emphasizing fermentable fiber patterns) to help steer the gut toward a healthier inflammatory and metabolic balance—potentially before symptoms such as chest discomfort, palpitations, dizziness, or leg swelling appear.

Medical Evidence

  • Scientific evidence level

    2 [weak—emerging but inconsistent; strongest evidence is mechanistic and observational, with limited causal and no validated clinical utility]

  • Clinical relevance note

    Current clinical relevance is low: although gut microbiome mechanisms plausibly intersect with atherosclerosis biology and observational studies report associations with CAD risk or markers, the evidence does not yet meet standards for causality or actionable decision-making. The main translational gap is that microbiome profiles have not been shown convincingly to (1) precede incident CAD in large, well-controlled prospective cohorts with robust external replication, (2) mediate causally independent risk (beyond diet, metabolic status, and medications), or (3) respond to interventions in a manner that reduces clinically meaningful CAD endpoints.

    In practice, gut microbiome testing is not validated for CAD risk stratification or monitoring, and using it to guide microbiome-targeted interventions would be premature. The best-supported near-term clinical relevance remains indirect: established CAD prevention (diet quality, smoking cessation, exercise, statins when indicated) likely influences the gut ecosystem and downstream metabolites, but the microbiome is best viewed currently as a research target and mechanistic mediator rather than a clinically actionable biomarker or treatment target.

Title Journal Year Link
Gut microbiome and risk of incident coronary artery disease in individuals with and without diabetes: a prospective cohort study The Lancet Diabetes & Endocrinology 2019 View →
Gut microbiota are associated with atherosclerotic plaque in humans Scientific Reports 2017 View →
The microbiome and cardiovascular disease: from pathogenesis to therapeutics Nature Reviews Cardiology 2014 View →
Microbial metabolite trimethylamine N-oxide (TMAO) promotes vascular inflammation and atherosclerosis Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2011 View →
Intestinal microbial metabolism of phosphatidylcholine promotes cardiovascular disease Nature Medicine 2011 View →

Frequently Asked Questions

    ¿Cuál es el vínculo entre el microbioma intestinal y el riesgo de CAD?
    El microbioma puede influir en la inflamación, el metabolismo de lípidos y la función vascular. Patrones de metabolitos como TMAO frente a SCFA podrían relacionarse con el riesgo, pero no es una causa única.
    ¿Qué es TMAO y por qué importa para CAD?
    TMAO es un metabolito producido por el hígado a partir de TMA generado por bacterias intestinales a partir de choline/L-carnitina; niveles más altos se han asociado con riesgo de CAD en algunos estudios; no probado como causal y no es un test diagnóstico.
    ¿Qué son los SCFA y por qué son protectores?
    Los ácidos grasos de cadena corta (p. ej., butirato) provienen de la fermentación de la fibra; fortalecen la barrera intestinal, modulando la inmunidad y el metabolismo; suelen ser beneficiosos.
    ¿Puede un test de microbioma predecir CAD?
    Puede dar contexto upstream y ayudar a personalizar la prevención, pero no es un diagnóstico por sí solo.
    ¿Qué cambios en la dieta pueden influir en el riesgo ligado al microbioma?
    Aumentar fibra fermentable (frutas, verduras, granos enteros, legumbres); limitar fuentes ricas en choline como ciertas carnes y huevos, según recomendaciones.
    ¿Qué patrones microbianos se asocian con mayor riesgo?
    Señales TMA/TMAO elevadas y menor producción de SCFA; patrones metabólicos, no especies individuales.
    ¿Cómo podría el microbioma influir en síntomas como dolor en el pecho?
    A través de inflamación y disfunción endotelial que afecta el flujo sanguíneo; los resultados no deben usarse como diagnóstico.
    ¿Qué es la disfunción endotelial?
    El revestimiento de los vasos no se relaja adecuadamente; paso temprano en la aterosclerosis.
    ¿Qué tan común es CAD y por qué importa el microbioma?
    CAD afecta a millones; el riesgo aumenta con la edad; el microbioma ofrece una capa adicional para entender el riesgo.
    ¿Qué es InnerBuddies y qué ofrece?
    Una herramienta que destaca señales del microbioma antes de los factores de riesgo clásicos y ayuda a interpretar los resultados con tu médico.
    ¿Los antibióticos o los IPP pueden afectar al microbioma y al riesgo de CAD?
    Sí, pueden cambiar la composición y función del microbioma y los metabolitos; uso bajo supervisión.
    ¿Cómo interpretar los resultados de un test de microbioma?
    Hable con su médico; pueden orientar cambios en el estilo de vida, pero no reemplazan un diagnóstico.
    ¿Existen pruebas de que la dieta modifique TMAO o SCFA?
    La dieta puede influir en el metabolismo microbiano; más fibra aumenta SCFA y puede modular señales de TMAO, con variabilidad individual.
    ¿Las pruebas de microbioma están recomendadas en guías?
    Actualmente es un área de investigación activa y no es una prueba diagnóstica estándar para CAD.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -